NRA-AZITHROMYCIN TABLET
Država: Kanada
Jezik: angleščina
Source: Health Canada
Lastnosti izdelka
(SPC)
03-02-2022
Nekateri dokumenti za ta izdelek trenutno niso na voljo, pošljete lahko zahtevo v našo stranko in obvestili vas bomo takoj, ko jih bomo lahko pridobili.
Pošlji zahtevo.
Pošlji zahtevo.
Aktivna sestavina:
AZITHROMYCIN (AZITHROMYCIN DIHYDRATE)
Dostopno od:
NORA PHARMA INC
Koda artikla:
J01FA10
INN (mednarodno ime):
AZITHROMYCIN
Odmerek:
600MG
Farmacevtska oblika:
TABLET
Sestava:
AZITHROMYCIN (AZITHROMYCIN DIHYDRATE) 600MG
Pot uporabe:
ORAL
Enote v paketu:
(3X10)/30/100/500
Tip zastaranja:
Prescription
Terapevtsko območje:
OTHER MACROLIDES
Povzetek izdelek:
Active ingredient group (AIG) number: 0126072005; AHFS:
Status dovoljenje:
APPROVED
Datum dovoljenje:
2018-08-02
Lastnosti izdelka
PRODUCT MONOGRAPH
Pr
NRA-AZITHROMYCIN
Azithromycin Dihydrate Tablets
250 mg and 600 mg Azithromycin (supplied as azithromycin dihydrate),
manufacturer’s standard
Antibacterial Agent
Control #: 260531
Nora Pharma Inc.
40 rue Prince-Arthur, Suite 310
Saint-Lambert, Québec, J4P 1X2
Date of Revision:
February 3, 2022
NRA-AZITHROMYCIN Product Monograph
Page 2 of 64
Table of Contents
PART I: HEALTH PROFESSIONAL
INFORMATION......................................................................
3
SUMMARY PRODUCT INFORMATION
......................................................................................
3
INDICATIONS AND CLINICAL USE
............................................................................................
3
CONTRAINDICATIONS
..................................................................................................................
4
WARNINGS AND PRECAUTIONS
................................................................................................
5
ADVERSE REACTIONS
..................................................................................................................
9
DRUG INTERACTIONS
................................................................................................................
15
DOSAGE AND ADMINISTRATION
............................................................................................
19
OVERDOSAGE
...............................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
...........................................................................
21
DETAILED PHARMACOLOGY).
.................................................................................................
22
STORAGE AND STABILITY
........................................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................................... 23
PART II: SCIENTIFIC INFORMATION
.................
Preberite celoten dokument
